HC Wainwright Issues Optimistic Estimate for Oculis Earnings

Oculis Holding AG (NASDAQ:OCS - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2025 earnings per share (EPS) estimates for shares of Oculis in a research note issued on Thursday, March 13th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings per share of ($0.43) for the quarter, up from their previous estimate of ($0.50). HC Wainwright has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.63) EPS.

A number of other research firms have also recently issued reports on OCS. Chardan Capital restated a "buy" rating and set a $28.00 price objective on shares of Oculis in a report on Thursday, March 13th. Robert W. Baird lifted their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th.

Oculis Trading Up 3.5 %

OCS traded up $0.65 during trading hours on Monday, reaching $19.39. 33,997 shares of the company's stock traded hands, compared to its average volume of 45,574. The firm has a 50-day moving average price of $20.96 and a 200 day moving average price of $17.11. Oculis has a 52-week low of $10.55 and a 52-week high of $23.08. The company has a quick ratio of 4.02, a current ratio of 4.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $846.78 million, a PE ratio of -10.00 and a beta of 0.01.

Remove Ads

Oculis (NASDAQ:OCS - Get Free Report) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%.

Institutional Investors Weigh In On Oculis

A number of institutional investors and hedge funds have recently bought and sold shares of OCS. Bellevue Group AG bought a new stake in Oculis during the 4th quarter valued at $170,000. XTX Topco Ltd bought a new position in shares of Oculis in the 4th quarter worth $225,000. Geode Capital Management LLC raised its position in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock worth $284,000 after acquiring an additional 1,800 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Oculis in the 4th quarter worth $389,000. Finally, Bank of America Corp DE raised its position in shares of Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock worth $493,000 after acquiring an additional 10,667 shares in the last quarter. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.